TY - JOUR
T1 - What is the true significance of donor-related cytomegalovirus transmission in the setting of facial composite tissue allotransplantation?
AU - Gordon, C. R.
AU - Abouhassan, W.
AU - Avery, R. K.
N1 - Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2011/11
Y1 - 2011/11
N2 - Face transplantation (FT) is fraught with complications parallel to solid organ transplantation (SOT). As such, donor-related cytomegalovirus (CMV) transmission remains one of the most commonly feared viruses associated with FT. With this in mind, a review of the literature seemed justified, knowing that two of the first four face transplant recipients acquired CMV donor-related viral infection. Although the risk of CMV transmission is acceptable in the setting of SOT, the scenario for those composite tissue allotransplantation (CTA) patients, who are often young and healthy, may be different. Experiences from France and Cleveland have both confirmed suboptimal events related to CMV transmission following transplantation. Therefore, using the information provided here, it is imperative that all FT teams remain aware of these potential risks. Furthermore, all patients pursuing facial CTA should be fully informed as to the risks of donor-related CMV transmission, understand the importance of prophylaxis, and be aware of alternative therapies required to prevent symptomatic disease.
AB - Face transplantation (FT) is fraught with complications parallel to solid organ transplantation (SOT). As such, donor-related cytomegalovirus (CMV) transmission remains one of the most commonly feared viruses associated with FT. With this in mind, a review of the literature seemed justified, knowing that two of the first four face transplant recipients acquired CMV donor-related viral infection. Although the risk of CMV transmission is acceptable in the setting of SOT, the scenario for those composite tissue allotransplantation (CTA) patients, who are often young and healthy, may be different. Experiences from France and Cleveland have both confirmed suboptimal events related to CMV transmission following transplantation. Therefore, using the information provided here, it is imperative that all FT teams remain aware of these potential risks. Furthermore, all patients pursuing facial CTA should be fully informed as to the risks of donor-related CMV transmission, understand the importance of prophylaxis, and be aware of alternative therapies required to prevent symptomatic disease.
UR - http://www.scopus.com/inward/record.url?scp=81455139651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81455139651&partnerID=8YFLogxK
U2 - 10.1016/j.transproceed.2011.08.043
DO - 10.1016/j.transproceed.2011.08.043
M3 - Article
C2 - 22099832
AN - SCOPUS:81455139651
SN - 0041-1345
VL - 43
SP - 3516
EP - 3520
JO - Transplantation proceedings
JF - Transplantation proceedings
IS - 9
ER -